Scarica l'app Stockscreener
8.625
3.09%
-0.285
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NVAX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$8.91
Aprire:
$8.93
Volume 24 ore:
2.80M
Relative Volume:
0.46
Capitalizzazione di mercato:
$1.40B
Reddito:
$1.08B
Utile/perdita netta:
$422.82M
Rapporto P/E:
3.7829
EPS:
2.28
Flusso di cassa netto:
$-637.33M
1 W Prestazione:
+0.52%
1M Prestazione:
+0.88%
6M Prestazione:
+39.27%
1 anno Prestazione:
-14.93%
Intervallo 1D:
$8.58
$9.10
Intervallo di 1 settimana:
$8.24
$9.34
Portata 52W:
$5.01
$11.55
Novavax Inc Stock (NVAX) Company Profile
Nome
Novavax Inc
Settore
Industria
Telefono
240-268-2000
Indirizzo
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Confronta NVAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.63 | 1.44B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.25 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
483.35 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.67 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
828.87 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.64 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-28 | Ripresa | H.C. Wainwright | Buy |
| 2025-08-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-06-17 | Iniziato | Citigroup | Sell |
| 2025-02-28 | Iniziato | BTIG Research | Buy |
| 2024-07-30 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Reiterato | B. Riley Securities | Buy |
| 2022-12-30 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-02 | Iniziato | Jefferies | Hold |
| 2022-09-22 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Iniziato | BofA Securities | Underperform |
| 2022-02-23 | Reiterato | B. Riley Securities | Buy |
| 2022-02-22 | Ripresa | Jefferies | Buy |
| 2022-01-21 | Iniziato | Cowen | Outperform |
| 2021-05-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Reiterato | B. Riley FBR | Buy |
| 2020-06-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Reiterato | B. Riley FBR | Buy |
| 2020-05-12 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2019-11-27 | Ripresa | B. Riley FBR | Buy |
| 2019-08-14 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-28 | Downgrade | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-12-11 | Iniziato | Oppenheimer | Outperform |
| 2018-11-26 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Aggiornamento | Seaport Global Securities | Neutral → Buy |
Mostra tutto
Novavax Inc Borsa (NVAX) Ultime notizie
Can Novavax’s Valuation Shift After Shah Capital Pushes for Company Sale? - Yahoo Finance
How Novavax Inc. stock compares to market leadersRisk Management & Free Community Consensus Stock Picks - newser.com
Intraday pattern recognizer results for Novavax Inc.July 2025 Breakouts & Expert Approved Momentum Trade Ideas - newser.com
Can Novavax Inc. stock sustain market leadershipShort Setup & Real-Time Chart Breakout Alerts - newser.com
Novavax Activist Investor Returns, This Time Pushing For Exit Strategy - insights.citeline.com
Top Novavax Shareholder Demands Company’s Sale - Barron's
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Benzinga
Shah Capital pushes for Novavax's sale on persistent underperformance, marketing missteps - Reuters
Shah Capital urges sale of Novavax amid continued vaccine sales struggles - The American Bazaar
Shah Capital Sends Letter to Novavax - MarketScreener
Novavax stock rises after major shareholder urges company sale By Investing.com - Investing.com Australia
Novavax stock rises after major shareholder urges company sale - Investing.com
Shah Capital Urges Sale of Novavax (NVAX) Amid COVID-19 Vaccine Struggles - GuruFocus
Novavax shareholder Shah Capital urges vaccine maker to explore sale amid market struggles - The Business Journals
Novavax top investor urges sale over poor COVID shot rollout; shares rise - TradingView
Shah Capital Pushes for Novavax (NVAX) Strategic Overhaul - GuruFocus
Novavax shareholder with large stake asks company to consider selling itself - Seeking Alpha
Investor seeks sale of Novavax after poor COVID jab sales - pharmaphorum
Novavax falls as top investor urges sale over poor COVID shot rollout - TradingView
Shah Capital recommends immediate formal strategic review for sale of Novavax - MarketScreener
New US COVID guidelines add confusion, complications for Americans seeking shots - MarketScreener
Will Novavax Inc. (NVV1) stock benefit from sector leadershipTrade Ideas & AI Enhanced Trading Signals - newser.com
Is Novavax Inc. stock attractive for retirement portfoliosBond Market & Real-Time Stock Entry Alerts - newser.com
Analyzing recovery setups for Novavax Inc. investors2025 Short Interest & High Accuracy Trade Signal Alerts - newser.com
Tools to assess Novavax Inc.’s risk profileRecession Risk & Fast Entry Momentum Trade Alerts - newser.com
What analysts say about Novavax Inc NVV1 stockSwing Trading Watchlist & High Profit Growth Stocks - earlytimes.in
Novavax Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
Novavax starts late-stage trial of COVID-19 vaccine in United States - Reuters
Novavax Inc. Stock Underperforms Friday When Compared To Competitors - 富途牛牛
Will Novavax Inc. continue its uptrendPortfolio Return Summary & Expert Approved Momentum Trade Ideas - newser.com
Statistical indicators supporting Novavax Inc.’s strengthJuly 2025 Analyst Calls & Real-Time Volume Spike Alerts - newser.com
Analyzing Novavax Inc. with risk reward ratio chartsTrade Ideas & Long-Term Investment Growth Plans - newser.com
Is Novavax Inc. stock attractive after correctionWeekly Volume Report & Weekly High Conviction Ideas - newser.com
Automated trading signals detected on Novavax Inc.2025 Volatility Report & Fast Entry High Yield Tips - newser.com
Is Novavax Inc. (NVV1) stock a buy on weakness2025 Pullback Review & Scalable Portfolio Growth Methods - newser.com
Is Novavax Inc. showing signs of accumulationMarket Performance Summary & Reliable Volume Spike Trade Alerts - newser.com
What institutional flow reveals about Novavax Inc.July 2025 Final Week & Fast Gain Stock Tips - newser.com
Novavax Inc Completes EU Marketing Authorization Transfer for Nuvaxovid - TradingView
Novavax Inc. Stock Slides 3.5%, Underperforms Peers - 富途牛牛
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
Novavax, Inc. Experiences Evaluation Revision Amid Mixed Market Performance Indicators - Markets Mojo
Novavax (NVAX) Transfers EU Vaccine Rights to Sanofi for $25M - GuruFocus
Shah Capital Management Has $72.52 Million Stock Position in Novavax, Inc. $NVAX - MarketBeat
Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU - Seeking Alpha
Novavax Continues to Deliver on Sanofi Partnership, Completion Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment - MarketScreener
Novavax Completes Transfer of Marketing Authorization for COVID-19 Vaccine in EU to Sanofi - MarketScreener
Sanofi (SNY) Gains Full EU Control of Nuvaxovid from Novavax - GuruFocus
Novavax receives $25 million milestone payment from Sanofi partnership - Investing.com
Novavax Transfers EU Vaccine Rights to Sanofi - TipRanks
$25M Milestone: Novavax Transfers Nuvaxovid EU Authorization to Sanofi; Eligible for Up to $350M - Stock Titan
Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment - Sahm
Novavax Inc Azioni (NVAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Novavax Inc Azioni (NVAX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Alton Gregg H | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
28,805 |
| King Rachel K. | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
25,190 |
| Rodgers Richard J | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
24,690 |
| MOTT DAVID M | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
60,890 |
| DOUGLAS RICHARD | Director |
Jun 12 '25 |
Option Exercise |
0.00 |
10,420 |
0 |
54,340 |
3.93%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):